- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02021110
Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease (CURSOR)
An International, Multicenter, Randomized Controlled Clinical Trial Assessing the Efficacy of Ursodeoxycholic Acid as a Volume Reducing Treatment in Symptomatic Polycystic Liver Disease
Rationale: Polycystic liver disease (PLD) is a rare disorder characterized by >20 fluid-filled hepatic cysts. Polycystic livers are present in the combination with renal cysts as a manifestation of autosomal dominant polycystic kidney disease (ADPKD), or isolated in the absence of renal cysts as autosomal dominant polycystic liver disease (ADPLD or PCLD). PLD patients are confronted with symptoms caused by the mass effect of their polycystic liver every day for the rest of their life. There is no standard therapeutic option for symptomatic PLD patients. Current options are fairly invasive or their efficacy is only moderate.
Preliminary data in our research lab have shown that ursodeoxycholic acid (UDCA) inhibited the proliferation of polycystic human cholangiocytes in vitro through the normalization of the intracellular calcium levels in cystic cholangiocytes. The investigators also found that daily oral administration of UDCA for 5 months to polycystic kidney disease (PCK) rats, an animal model of ARPKD that spontaneously develops hepato-renal cystogenesis, resulted in inhibition of hepatic cystogenesis.
The investigators hypothesize that UDCA is an effective therapeutic tool in reducing liver volume in PLD.
Objective: First, to demonstrate whether UDCA-therapy is effective in reducing total liver volume in PLD patients. Second, the investigators want to assess if UDCA modifies quality of life. Finally, the investigators want to assess safety and tolerability.
Study design: International, multicenter, randomized, controlled trial Study population: 34 subjects (18 ≤age ≤ 80 years) suffering from symptomatic polycystic liver disease with underlying diagnosis of (PCLD or ADPKD), defined as ≥ 20 liver cysts on CT-scan and liver volume of ≥ 2500. Symptomatic is defined as Eastern Cooperative Oncology Group- Performance Score (ECOG-PS) ≥ 1 and having at least three out of ten PLD symptoms.
Intervention: The patients will be randomized (1:1) into two groups. One group of patients will receive 15-20mg/kg/day UDCA for 24 weeks. The other group will receive standard care.
Main study endpoint: Proportional change of total liver volume in UDCA treated patients versus non treated patients, as assessed by CT at baseline and 6 months.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands
- Academic Medical Centre Amsterdam
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands
- Radboud University Medical Centre Nijmegen
-
-
-
-
-
San Sebastian, Spain
- Donostia University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 ≤ age ≤ 80 years
- Polycystic liver disease with underlying diagnosis of (PCLD or ADPKD), defined as ≥ 20 liver cysts
- Total liver volume ≥ 2500 mL
- Symptomatic defined as ECOG-PS ≥ 1 (2), and having at least three out of ten PCLD symptoms:
- Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements.
Exclusion Criteria:
- Use of oral anticonceptives or estrogen supplementation
- Use of UDCA in 3 months before baseline
- Females who are pregnant or breast-feeding or patients of reproductive potential not employing an effective method of birth control.
- Intervention (aspiration or surgical intervention) within six months before baseline
- Treatment with somatostatin analogues within six months before baseline
- Renal dysfunction (MDRD-Glomerular filtration rate< 30 ml/min/1.73m2)
- Patients with a kidney transplant
- Hypersensitivity reaction to UDCA or patients with galactose-intolerance, lactase deficiency or glucose-galactose malabsorption
- Acute cholecystitis or frequent biliary colic attacks
- Acute stomach or duodenal ulcers
- Inflammation of small intestine or colon
- Use of drugs that can interact with UDCA, such as colestyramine, aluminium hydroxide or cyclosporin
- Enrolment in another clinical trial of an investigational agent while participating in this study
- History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
- Mental illness that interferes with the patient ability to comply with the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control group
This group will receive standard care (no treatment)
|
|
Experimental: Ursodeoxycholic Acid
The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
|
The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of UDCA on total liver volume
Time Frame: Baseline to week 24
|
Proportional change of total liver volume in UDCA treated patients versus non treated patients, as assessed by CT at baseline and week 24
|
Baseline to week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of UDCA-therapy on absolute total liver volume
Time Frame: Baseline to week 24
|
Absolute total liver volume at baseline and end of treatment (week 24) will be measured
|
Baseline to week 24
|
Effect of UDCA on gastro-intestinal symptoms measured by a GI-questionnaire
Time Frame: Baseline to week 24
|
Improvement in Gastrointestinal Symptom score
|
Baseline to week 24
|
Effect of UDCA on health related quality of life as measured by Study Form -36
Time Frame: Baseline to week 24
|
Improvement in Study Form -36 score
|
Baseline to week 24
|
Proportion of patients with any reduction in total liver volume after 24 weeks
Time Frame: Baseline to week 24
|
Proportion reduction in total liver volume
|
Baseline to week 24
|
Effect of UDCA on absolute total kidney volume
Time Frame: Baseline to week 24
|
Change in total kidney volume after 24 weeks
|
Baseline to week 24
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events as a measure of tolerability and safety of UDCA
Time Frame: Baseline to week 24
|
All adverse events
|
Baseline to week 24
|
Collaborators and Investigators
Investigators
- Principal Investigator: Joost PH Drenth, dr., Radboud University Medical Centre Nijmegen, the Netherlands
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Kidney Diseases
- Urologic Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Pathological Conditions, Anatomical
- Abnormalities, Multiple
- Kidney Diseases, Cystic
- Ciliopathies
- Liver Diseases
- Polycystic Kidney Diseases
- Polycystic Kidney, Autosomal Dominant
- Cysts
- Gastrointestinal Agents
- Cholagogues and Choleretics
- Ursodeoxycholic Acid
Other Study ID Numbers
- PLD 11-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycystic Kidney, Autosomal Dominant
-
Emory UniversityPKD FoundationCompleted
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Mario Negri Institute for Pharmacological ResearchOtsuka Pharmaceutical Italy S.r.l.CompletedAutosomal Dominant Polycystic Kidney DiseaseItaly
-
Mayo ClinicUniversity of Kansas Medical CenterCompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
CHU de ReimsCompletedAutosomal Dominant Polycystic Kidney DiseaseFrance
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Regional Hospital HolstebroAarhus University HospitalCompletedAutosomal Dominant Polycystic Kidney DiseaseDenmark
-
University Hospital, BrestUnknownAutosomal Dominant Polycystic Kidney DiseaseFrance
-
Federico II UniversityCompletedAutosomal Dominant Polycystic Kidney Disease
-
Kadmon Corporation, LLCTerminatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)United States
Clinical Trials on Ursodeoxycholic Acid
-
Mitsubishi Tanabe Pharma CorporationCompletedChronic Hepatitis CJapan
-
University of Sao Paulo General HospitalCompletedPrimary Biliary Cirrhosis | Ursodeoxycholic AcidBrazil
-
University of TennesseeUniversity of Colorado, Denver; Baylor College of Medicine; Children's Hospital... and other collaboratorsCompletedPrimary Sclerosing CholangitisUnited States
-
West China HospitalUnknownHepatitis | Autoimmune | Primary Biliary CholangitisChina
-
Daewoong Pharmaceutical Co. LTD.CompletedHealthy SubjectKorea, Democratic People's Republic of
-
Institute of Hematology & Blood Diseases HospitalCompleted
-
Turku University HospitalCompletedPregnancy | Intrahepatic CholestasisFinland
-
Nottingham University Hospitals NHS TrustTerminated
-
HaEmek Medical Center, IsraelUnknown
-
Tanta UniversityMenoufia UniversityRecruiting